Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 226

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation

Zeimet, Alain G., Reimer, Daniel, Huszar, Monica, Winterhoff, Boris, Puistola, Ulla, Abdel Azim, Samira, Müller-Holzner, Elisabeth, Ben-Arie, Alon, van Kempen, Léon C., Petru, Edgar, Jahn, Stephan, Geels, Yvette P., Massuger, Leon F., Amant, Frédéric, Polterauer, Stephan, Lappi-Blanco, Elisa, Bulten, Johan, Meuter, Alexandra, Tanouye, Staci, Oppelt, Peter, Stroh-Weigert, Monika, Reinthaller, Alexander, Mariani, Andrea, Hackl, Werner, Netzer, Michael, Schirmer, Uwe, Vergote, Ignace, Altevogt, Peter, Marth, Christian, Fogel, Mina·2013·JNCI: Journal of the National Cancer Institute

Abstract

BACKGROUND: Despite the excellent prognosis of Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage I, type I endometrial cancers, a substantial number of patients experience recurrence and die from this disease. We analyzed the value of immunohistochemical L1CAM determination to predict clinical outcome. METHODS: We conducted a retrospective multicenter cohort study to determine expression of L1CAM by immunohistochemistry in 1021 endometrial cancer specimens. The Kaplan-Meier method and Cox proportional hazard model were applied for survival and multivariable analyses. A machine-learning approach was used to validate variables for predicting recurrence and death. RESULTS: Of 1021 included cancers, 17.7% were rated L1CAM-positive. Of these L1CAM-positive cancers, 51.4% recurred during follow-up compared with 2.9% L1CAM-negative cancers. Patients bearing L1CAM-positive cancers had poorer disease-free and overall survival (two-sided Log-rank P < .001). Multivariable analyses revealed an increase in the likelihood of recurrence (hazard ratio [HR] = 16.33; 95% confidence interval [CI] = 10.55 to 25.28) and death (HR = 15.01; 95% CI = 9.28 to 24.26). In the L1CAM-negative cancers FIGO stage I subdivision, grading and risk assessment were irrelevant for predicting disease-free and overall survival. The prognostic relevance of these parameters was related strictly to L1CAM positivity. A classification and regression decision tree (CRT)identified L1CAM as the best variable for predicting recurrence (sensitivity = 0.74; specificity = 0.91) and death (sensitivity = 0.77; specificity = 0.89). CONCLUSIONS: To our knowledge, L1CAM has been shown to be the best-ever published prognostic factor in FIGO stage I, type I endometrial cancers and shows clear superiority over the standardly used multifactor risk score. L1CAM expression in type I cancers indicates the need for adjuvant treatment. This adhesion molecule might serve as a treatment target for the fully humanized anti-L1CAM antibody currently under development for clinical use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djt144

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 226

Metadata

Authors
Zeimet, A. G., Reimer, D., Huszar, M., Winterhoff, B., Puistola, U., Abdel Azim, S., Müller-Holzner, E., Ben-Arie, A., van Kempen, L. C., Petru, E., Jahn, S., Geels, Y. P., Massuger, L. F., Amant, F., Polterauer, S., Lappi-Blanco, E., Bulten, J., Meuter, A., Tanouye, S., Oppelt, P., Stroh-Weigert, M., Reinthaller, A., Mariani, A., Hackl, W., Netzer, M., Schirmer, U., Vergote, I., Altevogt, P., Marth, C., & Fogel, M.
Venue
JNCI: Journal of the National Cancer Institute
Published
2013-06-18
Volume
105
Issue
15
Pages
1142-1150
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2161471989
Cited by
226
References
2
FWCI
20.04
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation. https://app.cochat.ai/papers/10.1093/jnci/djt144
The paper
Zeimet, A. G., Reimer, D., Huszar, M., Winterhoff, B., Puistola, U., Abdel Azim, S., Müller-Holzner, E., Ben-Arie, A., van Kempen, L. C., Petru, E., Jahn, S., Geels, Y. P., Massuger, L. F., Amant, F., Polterauer, S., Lappi-Blanco, E., Bulten, J., Meuter, A., Tanouye, S., . . . Fogel, M. (2013). L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djt144

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.